Intraluminal stent having coaxial polymer member

• US 6,530,950 B1
• Filed: 08/03/2000
• Issued: 03/11/2003
• Est. Priority Date: 01/12/1999
• Status: Expired due to Term

• Current Assignee: Quanam Medical Corp (Boston Scientific Corporation)
• Original Assignee: Quanam Medical Corp (Boston Scientific Corporation)
• Inventors: Pomerantseva, Irina D., Froix, Michael, Eury, Robert, Alvarado, Angelica
• Primary Examiner(s): Zalukaeva, Tatyana
• Application Number:
  US09/632,482
• Time in Patent Office: 950 Days
• Field of Search: 623/1, 623/1.13, 623/1.28, 623/12, 623/1.16, 623/1.2, 623/1.42, 623/1.1, 623/1.46, 526/319, 526/320, 526/323.1, 526/329, 526/329.2, 526/329.5
• US Class Current: 623/1.13
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61L 2300/00 Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 31/041 Mixtures of macromolecular compounds
• CPC Class Codes: A61L 31/048 obtained by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C08F 220/06 Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
• CPC Class Codes: C08F 220/14 Methyl esters , e.g. methyl (meth)acrylate
• CPC Class Codes: C08F 220/1804 C4-(meth)acrylate, e.g. butyl (meth)acrylate, isobutyl (meth)acrylate or tert-butyl (meth)acrylate
• CPC Class Codes: C08F 220/22 Esters containing halogen
• CPC Class Codes: C08F 220/286 and containing polyethylene oxide in the alcohol moiety, e.g. methoxy polyethylene glycol (meth)acrylate
• CPC Class Codes: C08F 222/102 of dialcohols, e.g. ethylene glycol di(meth)acrylate or 1,4-butanediol dimethacrylate
• CPC Class Codes: C08L 33/04 Homopolymers or copolymers of esters C08L43/04 takes precedence

Abstract

A stent for insertion into a lumen, having rigid regions and flexible regions along its length, and one or more polymer members coaxially disposed about the outer surface of the stent The polymer members are positioned over the rigid regions of the support stent, while the flexible regions are uncovered and free of polymer members, wherein the polymer members are radially expandable with the support stent.

Claims

1. A stent for insertion into a lumen, comprising;

a radially expandable, support stent having a selected axial length and an outer surface, said stent having rigid regions and flexible regions along its length; and

one or more polymer members coaxially disposed about the outer surface of the support stent, said polymer members positioned over the rigid regions of the support stent, with the flexible regions exposed, and said polymer members being radially expandable with the support stent.

2. The stent of claim 1, wherein said polymer members are composed of (i) between 10-98% of a first monomer composed of an aliphatic ester C1-C50 of acrylic acid which when homopolymerized has a glass transition temperature lower than about 25°

C.; and

(ii) a second monomer having sites of unsaturation and capable of free radical polymerization, the second monomer when homopolymerized having a glass transition temperature greater than 25°

C., said monomers when polymerized in the presence of a crosslinker forming a polymer having a glass transition temperature of less than about 25°

C.

3. The stent of claim 2, wherein the first monomer is an aliphatic ester of methacrylic acid or an aliphatic ester of acrylic acid.

4. The stent of claim 2, wherein the first monomer is fluorinated.

5. The stent of claim 2, wherein the first monomer is selected from butyl acrylate and pentafluoropropylacrylate.

6. The stent of claim 2, wherein said second monomer is selected from the group consisting of an ester of methacrylic acid, polyethylene glycol methacrylate monomer and polyethyleneglycol monomethylether methacrylate monomer.

7. The stent of claim 2, wherein the second monomer is selected from the group consisting of methylmethacrylate, isobornyl methacrylate, isobutyl methacrylate, perfluoroacetylmethacrylate, tertiary butylmethacrylate, phenylethylmethacrylate, styrene, hydroxyethyl methacrylate, glycerol methacrylate, n-vinyl pyrrolidone and heptadecylfluorodecyl-methacrylate.

8. The stent of claim 2, wherein the first monomer is pentafluoropropylacrylate and the second monomer is heptadecylfluorodecyl methacrylate.

9. The stent of claim 2, which further includes a third monomer of a methacrylic acid ester of polyethyeneoxide, where the ester side chain has a molecular weight of between 200-10,000 Daltons.

10. The stent of claim 7, therein the third monomer is selected from the group consisting of polyethyleneglycol dimethacrylate, polyethyleneglycol methacrylate and polyethyleneglycol acrylate.

11. The stent of claim 9, wherein the first monomer is butyl acrylate, the second monomer is methylmethacrylate and the third monomer is polyethylene oxide.

12. The stent of claim 9, wherein the first monomer is pentafluoropropylacrylate and the second monomer is methylmethacrylate and the third monomer is polyethylene oxide.

13. The stent of claim 2, which further includes a therapeutic agent.

14. The stent of claim 2, wherein the polymer members are composed of (a) greater than about 40 weight percent of butyl acrylate monomer;

(b) between 3-30 weight percent of methylmethacrylate monomer;

(c) between 2-40 weight percent of polyethylene glycol monomethylether monomethyacrylate;

said monomers when polymerized forming a polymer having a glass transition temperature of less than 25°

C.

15. The stent of claim 14, wherein the polymer forming the polymer members further includes one or more of the following components:

(a) between 0.1-20 weight percent of an organic solvent;

(b) a monomer effective to impart a charge to the polymer at physiologic pH;

(c) between 0.025-0.1 weight percent of a crosslinker;

(d) between 0.1-1 weight percent of a photoinitiator;

(e) a therapeutic agent.

16. The stent of claim 15, wherein the solvent is dimethylformamide in an amount between 1-15 weight percent.

17. The stent of claim 16, further including a therapeutic agent.